DUBLIN, Ireland, April 01, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the 23rd Annual Needham Healthcare Conference on Monday, April 8 at 10:15 a.m. ET.
A live webcast of the fireside chat, as well as an archived recording, will be available on Avadel’s Investor Relations website, investors.avadel.com, for 90 days following the conference.
About Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Avadel’s commercial product, LUMRYZ™, was approved by the U.S. Food & Drug Administration (FDA) as the first and only once-at-bedtime oxybate for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. For more information, please visit www.avadel.com.
Investor Contact:
Courtney Mogerley
Stern Investor Relations, Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.
(212) 698-8687
Media Contact:
Lesley Stanley
Real Chemistry
This email address is being protected from spambots. You need JavaScript enabled to view it.
(609) 273-3162
| Last Trade: | US$7.90 |
| Daily Change: | -2.79 -26.10 |
| Daily Volume: | 7,849,135 |
| Market Cap: | US$761.240M |
January 08, 2025 November 12, 2024 October 24, 2024 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
